Torii Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Torii Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Torii Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Torii Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Torii Pharmaceutical Co., Ltd. (Torii), a subsidiary of Shionogi & Co., Ltd., is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and commercialization of prescription medicines. The company concentrates on specialty therapeutic areas where long-term disease management and improved quality of life are critical, primarily chronic kidney disease (CKD) and dialysis-related complications, dermatology, and allergic diseases, including allergen immunotherapy.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Torii is actively advancing its research and development (R&D) initiatives through strategic partnerships. The company has signed a license agreement with Vertica Pharmaceuticals Inc for the exclusive development and commercialization of TO-208, aimed at treating Molluscum contagiosum in Japan. Torii has partnered with Nogra Pharma Limited for TO-210, focusing on acne treatment. The company has secured exclusive development and sales rights in Japan for TO-203, Miticure Sublingual Tablets, targeting house dust mite-induced allergic asthma, in collaboration with ALK-Abello.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer